Aim: The aim of the research was to investigate the effects of Valsartan therapy on QT interval dispersion (QTd) in patients with Chronic Heart Failure (CHF). Material and Method: A sample of ambulatory patients, aged 22-79 years in NYHA class II to IV, with ventricular ejection fraction < 45 %, were followed prospectively. The patients were evaluated for hypertension, diabetes mellitus, smoking, alcohol abuse, concomitant medications, and QTd. Valsartan therapy was initiated in a dose of 80 mg once a day. Six months later, the patient were re-evaluated. Twelve lead electrocardiogram was recorded prior to and after 6 months Valsartan therapy. Data were analyzed according to the distribution at a significance level of 5% by using Statistica 6.0 software. Results: Eighty ambulatory patients were included in the study and they were divided into: group I, aged ≤ 65 years (n= 44), and group II, aged > 65 years (n = 36). At 6 months, there were identified on both groups that QTd significantly decreased comparing with baseline values (85 ms vs 112 ms; Wilcoxon Z = 7.77, n = 80, p < 0.001). Conclusions: The results of the study showed that, in ambulatory patients with CHF, 6 months Valsartan therapy significantly decreases QTd. The decrease of the QTd was uniformly distributed between patients aged ≤ 65 years and those aged > 65 years. The reduction in QTd in patients with CHF using Valsartan could be responsible by the reduction in the risk of sudden cardiac death in the investigated group.


Congestive heart failure, QT dispersion (QTd), Valsartan, Therapy.